uniQure reported ongoing Phase I/II study results for ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease, indicating a 44% reduction in disease progression at 48 months in high-dose patients.

Observed price moves

• QURE-12.72%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.